🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?

Dr. Kuykendall presents VERIFY: rusfertide vs placebo for polycythemia vera. During weeks 20-32, more patients who received rusfertide achieved a clinical response, 76.9 vs 32.9%, p<0.0001. Patients received fewer phlebotomies and had less fatigue. #ASCO25

Dr. Katherine Walsh points out the dramatic changes in phlebotomy independence and hematocrit control along with significant symptom reduction. #ASCO25

Not even an oral abstract for colorectal cancer! #ASCO25

Dr. Yelena Y. Janjigian with MATTERHORN: - durvalumab + FLOT in resectable gastric/GEJ cancer. - EFS NR vs 32.8 months, HR 0.71, p<0.001 - Overall survival not significant (yet?) with follow-up ongoing - Adverse events as expected #ASCO25

Dr. Klempner shows the landscape of resectable gastric cancer treatment and suggests MATTERHORN should change practice TODAY. #ASCO25

Dr. Mark Lewis brings us full circle to focus on the patient at the center of all of our work. #ASCO25

Dr. Char presents: association between empirical dietary inflammatory pattern (EDIP) and survival in patients w/ stage III colon cancer: Extreme pro-inflammatory diet had worse overall survival (HR 1.87), not statistically different DFS. #ASCO25

Dr. Booth presents CHALLENGE, evaluating exercise in stage II-III colon cancer after adjuvant chemo. Intervention was a funded personal trainer / PT / kinesiologist for 3 years to increase physical activity by 10 MET/hrs/wk above baseline. DFS HR 0.72, p=0.017 #ASCO25

Number needed to cure is 16!

CHALLENGE overall survival 0.63, 90 vs 83%. Musculoskeletal adverse events increased to 19 vs 12%. Several physiologic functions improved. Structured program is critical! #ASCO25

This is what I’ll take away from #ASCO25. And two additional points: 1. It received a standing ovation 2. Did not have to say overall survival data hadn’t matured … in contrast to the plenary session’s abstracts. It should have been included!

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.